(Q44473067)

3 December 2017

title

Effects of Hypericum perforatum and paroxetine on rat performance in the elevated T-maze (English)

1 reference

3 December 2017

Hypericum perforatum

1 reference

Venessa Beijamini

1

1 reference

3 December 2017

Roberto Andreatini

series ordinal

2

1 reference

3 December 2017

publication date

1 August 2003

1 reference

3 December 2017

published in

Pharmacological Research

1 reference

3 December 2017

volume

48

1 reference

3 December 2017

issue

2

1 reference

3 December 2017

page(s)

199-207

1 reference

The elevated T-maze: a new animal model of anxiety and memory.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Behavioral validation of the elevated T-maze, a new animal model of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

The elevated T-maze as an experimental model of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

5-HT and mechanisms of defence

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Hypericum perforatum--a review of clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

St John's wort for depression--an overview and meta-analysis of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

St. John's wort for depression: a meta-analysis of well-defined clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

St John's wort: Prozac from the plant kingdom.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Effectiveness of St John's wort in major depression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Efficacy of an Hypericum perforatum (St. John's wort) extract in preventing and reverting a condition of escape deficit in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Hyperforin as a possible antidepressant component of hypericum extracts

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

St. John's wort in generalized anxiety disorder: three case reports

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Hypericum for fatigue - a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Comparative evaluation of Melissa officinalis L., Tilia europaea L., Passiflora edulis Sims. and Hypericum perforatum L. in the elevated plus maze anxiety test

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Evidence that total extract of Hypericum perforatum affects exploratory behavior and exerts anxiolytic effects in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Effects of acute and chronic treatment with Hypericum perforatum L. (LI 160) on different anxiety-related responses in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Effects of Hypericum perforatum and paroxetine in the mouse defense test battery.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Behavioural despair in rats: A new model sensitive to antidepressant treatments

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

The effect of oxcarbazepine on behavioural despair and learned helplessness.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Effects of Hypericum perforatum extract on ethanol intake, and on behavioral despair: a search for the neurochemical systems involved

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Anxiolytic-like effect of paroxetine in a rat social interaction test

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Role of CCK in anti-exploratory action of paroxetine, 5-HT reuptake inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Paroxetine efficacy in the treatment of generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Activity profiles of two hyperforin-containing hypericum extracts in behavioral models

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2803%2900097-5

7 January 2021

10.1016/S1043-6618(03)00097-5

Identifiers

DOI

1 reference

3 December 2017

1 reference